Blood CD34-c-Kit+ cell rate correlates with aggressive forms of systemic mastocytosis and behaves like a mast cell precursor

Blood

Volumn 118, Issue 19, 2011, Pages 5246-5249

  Georgin Lavialle, Sophie ^a,b   Lhermitte, Ludovic ^a   Baude, Cédric ^c   Barete, Stéphane ^b,c,d   Bruneau, Julie ^b   Launay, Jean Marie ^e   Chandesris, Marie Olivia ^a   Hanssens, Katia ^b   De Gennes, Christian ^f   Damaj, Gandhi ^g   Lanternier, Fanny ^a   Hamidou, Mohamed ^h   Lortholary, Olivier ^a,c   Dubreuil, Patrice ^b,c   Feger, Frédéric ^b   Lepelletier, Yves ^b   Hermine, Olivier ^a,b,c  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b CNRS   (France)

^c Association Francaise Initiatives Recherche Mastocytes Mastocytoses AFIRMM   (France)

^d HÔPITAL TENON   (France)

^e HÔPITAL LARIBOISIÈRE   (France)

^f PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^g AMIENS UNIVERSITY HOSPITAL   (France)

^h HÔTEL DIEU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; STEM CELL FACTOR; TRYPTASE;

ADULT; AGED; AGGRESSIVE SYSTEMIC MASTOCYTOSIS; ARTICLE; CHILD; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HUMAN; HUMAN CELL; INDOLENT SYSTEMIC MASTOCYTOSIS; MALE; MAST CELL; MAST CELL PRECURSOR; MASTOCYTOSIS; PHENOTYPE; PRIORITY JOURNAL; SCHOOL CHILD; STEM CELL; SYSTEMIC MASTOCYTOSIS; SYSTEMIC MASTOCYTOSIS WITH ASSOCIATED HEMATOLOGIC NON MAST CELL LINEAGE DISEASE; URTICARIA PIGMENTOSA;

EID: 81155151867     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-02-335950     Document Type: Article

References (23)

1. Horny HP, Parwaresch MR, Lennert K. Bone marrow findings in systemic mastocytosis. Hum Pathol. 1985;16(8):808-814. (Pubitemid 15040816)
2. Lennert K, Parwaresch MR. Mast cells and mast cell neoplasia: a review. Histopathology. 1979;3(5):349-365. (Pubitemid 9249267)
3. Metcalfe DD. Classification and diagnosis of mastocytosis: current status. J Invest Dermatol. 1991;96(3 suppl):2S-4S.
4. Valent P. Biology, classification and treatment of human mastocytosis. Wien Klin Wochenschr. 1996;108(13):385-397. (Pubitemid 26229031)
5. Valent P, Horny HP, Escribano L, et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res. 2001;25(7):603-625. (Pubitemid 32506768)
6. Valent P, Escribano L, Longley BJ, et al., eds. Mastocytosis (mast cell disease). In: Jaffe ES, Stein H, Vardiman JW, eds. World Health Organization (WHO) Classification of Tumours. Lyon, France: IARC Press; 2001:291-302.
7. Valent P, Akin C, Sperr WR, Horny HP, Metcalfe DD. Mast cell proliferative disorders: current view on variants recognized by theWorld Health Organization. Hematol Oncol Clin North Am. 2003;17(5):1227-1241. (Pubitemid 37187806)
8. Valent P, Schernthaner GH, Sperr WR, et al. Variable expression of activation-linked surface antigens on human mast cells in health and disease. Immunol Rev. 2001;179:74-81. (Pubitemid 32171275)
9. Escribano L, Diaz-Agustin B, Bellas C, et al. Utility of flow cytometric analysis of mast cells in the diagnosis and classification of adult mastocytosis. Leuk Res. 2001;25(7):563-570. (Pubitemid 32506763)
10. Escribano L, Diaz-Agustin B, Lopez A, et al. Immunophenotypic analysis of mast cells in mastocytosis: when and how to do it. Proposals of the Spanish Network on Mastocytosis (REMA). Cytometry B Clin Cytom. 2004;58(1):1-8. (Pubitemid 38332714)
11. Escribano L, Diaz-Agustin B, Nunez R, Prados A, Rodriguez R, Orfao A. Abnormal expression of CD antigens in mastocytosis. Int Arch Allergy Immunol. 2002;127(2):127-132. (Pubitemid 34264200)
12. Escribano L, Orfao A, Diaz-Agustin B, et al. Indolent systemic mast cell disease in adults: immunophenotypic characterization of bone marrow mast cells and its diagnostic implications. Blood. 1998;91(8):2731-2736. (Pubitemid 28227522)
13. Escribano L, Orfao A, Villarrubia J, et al. Sequential immunophenotypic analysis of mast cells in a case of systemic mast cell disease evolving to a mast cell leukemia. Cytometry. 1997;30(2):98-102. (Pubitemid 27240014)
14. Teodosio C, Garcia-Montero AC, Jara-Acevedo M, et al. Mast cells from different molecular and prognostic subtypes of systemic mastocytosis display distinct immunophenotypes. J Allergy Clin Immunol. 2010;125(3):719-726.
15. Kirshenbaum AS, Goff JP, Semere T, Foster B, Scott LM, Metcalfe DD. Demonstration that human mast cells arise from a progenitor cell population that is CD34(+), c-kit(+), and expresses aminopeptidase N (CD13). Blood. 1999;94(7):2333-2342. (Pubitemid 29467681)
16. Arock M, Le Nours A, Malbec O, Daeron M. Ex vivo and in vitro primary mast cells. Methods Mol Biol. 2008;415:241-254.
17. Lebel B. A high-sampling-rate automated continuous- flow fluorometric technique for the analysis of nanogram levels of histamine in biological samples. Anal Biochem. 1983;133(1):16-29. (Pubitemid 13009667)
18. Bodemer C, Hermine O, Palmerini F, et al. Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations. J Invest Dermatol. 2010;130(3):804-815.
19. Hahn KA, Ogilvie G, Rusk T, et al. Masitinib is safe and effective for the treatment of canine mast cell tumors. J Vet Intern Med. 2008;22(6):1301- 1309.
20. Schwartz LB, Bradford TR, Rouse C, et al. Development of a new, more sensitive immunoassay for human tryptase: use in systemic anaphylaxis. J Clin Immunol. 1994;14(3):190-204. (Pubitemid 24182179)
21. Sperr WR, Jordan JH, Baghestanian M, et al. Expression of mast cell tryptase by myeloblasts in a group of patients with acute myeloid leukemia. Blood. 2001;98(7):2200-2209.
22. Lim KH, Tefferi A, Lasho TL, et al. Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. Blood. 2009;113(23):5727-5736.
23. Pardanani A, Lim KH, Lasho TL, et al. Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies. Blood. 2009;114(18):3769-3772.